FCSC - Fibrocell Science, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Fibrocell Science, Inc.

405 Eagleview Boulevard
Exton, PA 19341
United States
484-713-6000
http://www.fibrocell.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees23

Key Executives

NameTitlePayExercisedAge
Mr. John Michael MaslowskiPres, CEO, PFO, Principal Accounting Officer & Director337.4kN/A42
Mr. Robert G. PartridgeVP of Global Marketing, Communications and Investor RelationsN/AN/AN/A
Ms. Elizabeth A. BrowningExec. VP of MarketingN/AN/AN/A
Ms. Michele Mchugh-MazzattaVP of SalesN/AN/AN/A
Dr. Pierre CompteManaging Director of SwitzerlandN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company's gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Corporate Governance

Fibrocell Science, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.